Dr. Lal PathLabs is currently trading at Rs. 2771.95, up by 31.85 points or 1.16% from its previous closing of Rs. 2740.10 on the BSE.
The scrip opened at Rs. 2740.15 and has touched a high and low of Rs. 2794.40 and Rs. 2740.15 respectively. So far 5048 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3645.00 on 10-Oct-2024 and a 52 week low of Rs. 2295.10 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 2934.75 and Rs. 2730.60 respectively. The current market cap of the company is Rs. 23222.15 crore.
The promoters holding in the company stood at 53.91%, while Institutions and Non-Institutions held 39.99% and 6.10% respectively.
Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, the company can now deliver faster and more accurate genomic research insights.
The NovaSeq X system features Illumina’s cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what’s possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements.
Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing (NGS), enabling the company to deliver actionable, AI-powered insights with greater speed and sensitivity.
Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.
| Company Name | CMP |
|---|---|
| Apollo Hospital Ent. | 7699.05 |
| Max Healthcare Inst | 1006.90 |
| Narayana Hrudayalay | 1825.55 |
| Aster DM Healthcare | 688.30 |
| Global Health | 1089.55 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: